Piperacillin/Tazobactam
General
- Type: Anti-Pseudomonal Penicillin
- Dosage Forms:
- Common Trade Names: Zosyn
Adult Dosing
General
- 3.375 g IV q6 hours
- Alt: 4.5 g q6-8 hours
- Max: 18 g/day
Diverticulitis
- 3.375 g IV q6 hours x 7-10 days
Pneumonia
- CAP
- 3.375 g IV q6 hours x 7-10 days
- Only for P. aeruginosa caused or from aspiration[1]
- Nosocomial
- 4.5 g IV q6 hours x 7-14 days
- + aminoglycoside or antipseudomonal fluoroquinolone
Pediatric Dosing[2]
A Piperacillin/Taxobactam 3.375g vial contains 3g piperacillin and 0.375g tazobactam (8:1 ratio)
General
- <2 months
- 100 mg piperacillin/kg/dose IV q6 hours
- 2-9 months
- 80 mg piperacillin/kg/dose IV q8 hours
- >9 months
- 100 mg piperacillin/kg/dose q8 hours
- Max: 16 g/day
Appendicitis and/or Peritonitis
- 2-9 months
- 80 mg piperacillin/kg/dose IV q8 hours
- >9 months
- ≤40 kg: 100 mg piperacillin/kg/dose IV q8 hours
- >40 kg: 3.375g (3000 mg piperacillin) IV q6 hours
- Max: 16 g/day
Cystic Fibrosis, Pseudomonal Infection
- 240-400 mg piperacillin/kg/day IV divided q8 hours;
- Consider higher dose: 450-600 mg/kg/day IV divided q4-6 hours[3]
Special Populations
- Pregnancy:
- Lactation:
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action:
Antibiotic Sensitivities[4]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
Source
- ↑ Mandell, 2007
- ↑ Red Book, 2012
- ↑ Zobell JT, Waters CD, Young DC, et al, "Optimization of Anti-Pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: II. Cephalosporins and Penicillins," Pediatr Pulmonol, 2013, 48(2):107-22. PubMed 22949297
- ↑ Sanford Guide to Antimicrobial Therapy 2014